A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study

被引:34
|
作者
Scott, Russell [1 ]
Morgan, Jerry [2 ]
Zimmer, Zachary [2 ]
Lam, Raymond L. H. [2 ]
O'Neill, Edward A. [2 ]
Kaufman, Keith D. [2 ]
Engel, Samuel S. [2 ]
Raji, Annaswamy [2 ]
机构
[1] Christchurch Sch Med, Lipid & Diabet Res Grp, Christchurch, New Zealand
[2] Merck & Co Inc, Kenilworth, NJ USA
来源
DIABETES OBESITY & METABOLISM | 2018年 / 20卷 / 12期
关键词
clinical trial; dapagliflozin; sitagliptin; type; 2; diabetes; POOLED ANALYSIS; KIDNEY-DISEASE; INHIBITORS; EQUATION;
D O I
10.1111/dom.13473
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim Materials and Methods To compare the efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin with the sodium-glucose transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes and mild renal insufficiency. Patients with HbA1c >= 7.0 to <= 9.5% (>= 53 to <= 80 mmol/mol) and estimated glomerular filtration rate >= 60 to <90 mL/min/1.73m(2) on metformin (>= 1500 mg/d) +/- sulfonylurea were randomized to sitagliptin 100 mg (n = 307) or dapagliflozin 5 mg titrated to 10 mg (n = 306) once daily for 24 weeks. A longitudinal data analysis model was used to test the primary hypothesis that sitagliptin is non-inferior to dapagliflozin in reducing HbA1c at Week 24, with superiority to be tested if non-inferiority is met. NCT02532855. Results Conclusions Baseline mean HbA1c (% [mmol/mol]) was 7.7 (60.9) and 7.8 (61.2), and mean eGFR (mL/min/1.73m(2)) was 79.4 and 76.9 for the sitagliptin and dapagliflozin groups, respectively. After 24 weeks, the between-group difference in least squares mean (95% CI) changes from baseline in HbA1c was -0.15% (-0.26, -0.04) (-1.67 mmol/mol [-2.86, -0.48]), P = 0.006, meeting the prespecified criteria for declaring both non-inferiority and superiority of sitagliptin versus dapagliflozin. The HbA1c goal of <7% (<53 mmol/mol) was met by 43% (sitagliptin) and 27% (dapagliflozin) of patients. No meaningful between-group difference was observed in a pre-specified analysis of 2-hour incremental postprandial glucose excursion. A review of adverse events (AEs) was notable for a lower incidence of drug-related AEs with sitagliptin compared with dapagliflozin. In patients with type 2 diabetes, mild renal insufficiency and inadequate glycaemic control on metformin +/- sulfonylurea, sitagliptin treatment resulted in greater improvement in glycaemic control compared with dapagliflozin and was generally well tolerated.
引用
收藏
页码:2876 / 2884
页数:9
相关论文
共 50 条
  • [41] Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial
    Han, Kyung-Ah
    Chon, Suk
    Chung, Choon Hee
    Lim, Soo
    Lee, Kwan-Woo
    Baik, SeiHyun
    Jung, Chang Hee
    Kim, Dong-Sun
    Park, Kyong Soo
    Yoon, Kun-Ho
    Lee, In-Kyu
    Cha, Bong-Soo
    Sakatani, Taishi
    Park, Sumi
    Lee, Moon-Kyu
    [J]. DIABETES OBESITY & METABOLISM, 2018, 20 (10): : 2408 - 2415
  • [42] Efficacy and Safety of Sitagliptin in Patients With Type 2 Diabetes and ESRD Receiving Dialysis: A 54-Week Randomized Trial
    Ferreira, Juan C. Arjona
    Corry, Dalila
    Mogensen, Carl E.
    Sloan, Lance
    Xu, Lei
    Golm, Gregory T.
    Gonzalez, Edward J.
    Davies, Michael J.
    Kaufman, Keith D.
    Goldstein, Barry J.
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2013, 61 (04) : 579 - 587
  • [43] Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial
    Oh, Tae Jung
    Yu, Jae Myung
    Min, Kyung Wan
    Son, Hyun Shik
    Lee, Moon Kyu
    Yoon, Kun Ho
    Song, Young Duk
    Park, Joong Yeol
    Jeong, In Kyung
    Cha, Bong Soo
    Kim, Yong Seong
    Baik, Sei Hyun
    Kim, In Joo
    Kim, Doo Man
    Kim, Sung Rae
    Lee, Kwan Woo
    Park, Jeong Hyung
    Lee, In Kyu
    Park, Tae Sun
    Choi, Sung Hee
    Park, Sung Woo
    [J]. DIABETES & METABOLISM JOURNAL, 2019, 43 (03) : 276 - 286
  • [44] Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes A Prespecified Secondary Analysis of a Randomized Clinical Trial
    Oyama, Kazuma
    Raz, Itamar
    Cahn, Avivit
    Goodrich, Erica L.
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John P. H.
    Gause-Nilsson, Ingrid A. M.
    Mosenzon, Ofri
    Sabatine, Marc S.
    Wiviott, Stephen D.
    [J]. JAMA CARDIOLOGY, 2022, 7 (09) : 914 - 923
  • [45] Comparison of therapeutic efficacy and safety of sitagliptin, dapagliflozin, or lobeglitazone adjunct therapy in patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea and metformin: Third agent study
    Hong, Jun Hwa
    Moon, Jun Sung
    Seong, Kayeon
    Lim, Soo
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 203
  • [46] Efficacy and Renal Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus Also Receiving Metformin: A Real-Life Experience
    Scorsone, Alessandro
    Saura, Gabriella
    Fleres, Mattia
    Spano, Lucia
    Aiello, Vito
    Brancato, Davide
    Di Noto, Anna
    Provenzano, Francesca
    Provenzano, Vincenzo
    [J]. JOURNAL OF DIABETES RESEARCH, 2018, 2018
  • [47] Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin A Randomized Trial
    Wilding, John P. H.
    Woo, Vincent
    Soler, Norman G.
    Pahor, Andrea
    Sugg, Jennifer
    Rohwedder, Katja
    Parikh, Shamik
    [J]. ANNALS OF INTERNAL MEDICINE, 2012, 156 (06) : 405 - U50
  • [48] Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial
    Wilding, J. P. H.
    Woo, V.
    Soler, N. G.
    Pahor, A.
    Sugg, J.
    Rohwedder, K.
    Parikh, S.
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2013, 138 : S27 - S38
  • [49] Influence of cardiovascular drugs on the efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial
    Oyama, K.
    Raz, I.
    Cahn, A.
    Goodrich, E.
    Bhatt, D.
    Leiter, L.
    McGuire, D.
    Wilding, J.
    Gause-Nilsson, I.
    Mosenzon, O.
    Sabatine, M.
    Wiviott, S.
    [J]. EUROPEAN HEART JOURNAL, 2021, 42 : 2961 - 2961
  • [50] Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Type 2 Diabetes A Randomized Clinical Trial
    Russo, Cristina
    Walicka, Magdalena
    Caponnetto, Pasquale
    Cibella, Fabio
    Maglia, Marilena
    Alamo, Angela
    Campagna, Davide
    Frittitta, Lucia
    Di Mauro, Maurizio
    Caci, Grazia
    Krysinski, Arkadiusz
    Franek, Edward
    Polosa, Riccardo
    [J]. JAMA NETWORK OPEN, 2022, 5 (06) : E2217709